Table 1.
Clinical trials using anti-MSLN CAR-T therapy for solid tumors.
| NCT Number | Title | Status | Type of Cancer | Phase | Enrollment | Start Date | Publication |
|---|---|---|---|---|---|---|---|
| NCT05531708 | Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors | Recruiting | Refractory Solid Tumors | Phase 1 | 20 | 8 September 2022 | |
| NCT05373147 | αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors | Recruiting | Solid Tumor | Early Phase 1 |
21 | 13 May 2022 | |
| NCT05623488 | CAR T Cells in Mesothelin-Expressing Breast Cancer | Not yet recruiting | Breast Cancer | Phase 1 | 12 | 21 November 2022 | |
| NCT05089266 | Study of αPD1-MSLN-CAR-T Cells to Evaluate the Safety, Tolerability, and Effectiveness for Patients with MSLN-Positive Advanced Solid Tumors | Not yet recruiting | Colorectal Cancer | Phase 1 | 30 | 30 November 2021 | |
| NCT05057715 | huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer | Not yet recruiting | Pancreatic Cancer, Serous Ovarian Cancer | Phase 1 | 12 | 1 December 2021 | |
| NCT04981691 | Anti-Mesothelin CAR-T Cells with Advanced Refractory Solid Tumors | Recruiting | Refractory Malignant Solid Neoplasm | Phase 1 | 12 | 1 October 2021 | |
| NCT04577326 | Mesothelin-Targeted CAR-T-cell Therapy in Patients with Mesothelioma | Recruiting | Malignant Pleural Mesothelioma (MPM) | Phase 1 | 30 | 30 September 2020 | |
| NCT04562298 | A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T-Cell Therapy Targeting MSLN in Patients with Relapsed and Refractory Epithelial Ovarian Cancer | Recruiting | Epithelial Ovarian Cancer | Phase 1 | 34 | 21 October 2020 | |
| NCT04503980 | αPD1-MSLN-CAR-T Cells for the Treatment of MSLN-Positive Advanced Solid Tumors | Recruiting | Colorectal Cancer, Ovarian Cancer | Early Phase 1 | 10 | 26 March 2020 | |
| NCT04489862 | αPD1-MSLN-CAR-T Cells for the Treatment of MSLN-Positive Advanced Solid Tumors | Recruiting | Non-Small Cell Lung Cancer, Mesothelioma | Early Phase 1 | 10 | 13 May 2020 | |
| NCT04203459 | The Mechanism of Enhancing the Antitumor Effects of CAR-T on PC by Gut Microbiota Regulation | Recruiting | Pancreatic Cancer | 80 | 20 October 2019 | ||
| NCT03941626 | Autologous CAR-T/TCR-T-Cell Immunotherapy for Solid Malignancies | Recruiting | Esophageal Cancer, Hepatoma, Glioma, Gastric Cancer | Phase 1 Phase 2 | 50 | 1 September 2019 | |
| NCT03916679 | MESO-CAR-T-Cell Therapy Relapsed and Refractory Epithelial Ovarian Cancer | Recruiting | Ovarian Cancer | Phase 1 Phase 2 | 20 | 20 April 2019 | |
| NCT03814447 | Fourth-Generation CAR-T-Cell Therapy for Refractory-Relapsed Ovarian Cancer | Recruiting | Ovarian Cancer | Early Phase 1 | 10 | 16 August 2019 | |
| NCT03799913 | meso-CAR-T-Cell Therapy Relapsed and Refractory Ovarian Cancer | Recruiting | Ovarian Cancer | Early Phase 1 | 20 | 10 April 2019 | |
| NCT03747965 | Study of PD-1 Gene-Knocked Out Mesothelin-Directed CAR-T Cells with the Conditioning of PC in Mesothelin-Positive Multiple Solid Tumors | Unknown status | Solid Tumor | Phase 1 | 10 | 1 November 2018 | |
| NCT03638193 | Study of Autologous T Cells in Patients with Metastatic Pancreatic Cancer | Recruiting | Pancreatic Cancer | Not Applicable | 10 | 11 July 2018 | |
| NCT03615313 | PD-1 Antibody-Expressing Meso-CAR-T Cells for Mesothelin-Positive Advanced Solid Tumor | Unknown status | Advanced Solid Tumor | Phase 1 Phase 2 | 50 | 6 August 2018 | |
| NCT03608618 | Intraperitoneal MCY-M11 (Mesothelin-Targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma | Terminated | Peritoneal Mesothelioma, Fallopian Tube Adenocarcinoma, Adenocarcinoma of the Ovary, Primary Peritoneal Carcinoma | Phase 1 | 14 | 27 August 2018 | |
| NCT03545815 | Study of CRISPR—Cas9-Mediated PD-1 and TCR Gene-Knocked Out Mesothelin-Directed CAR-T Cells in Patients with Mesothelin-Positive Multiple Solid Tumors | Recruiting | Solid Tumor | Phase 1 | 10 | 19 March 2018 | PMID: 34381179 |
| NCT03497819 | Autologous CART-meso/19 Against Pancreatic Cancer | Unknown status | Pancreatic Cancer | Early Phase 1 | 10 | 1 October 2017 | |
| NCT03356808 | Antigen-Specific T Cells Against Lung Cancer | Unknown status | Lung Cancer | Phase 1 Phase 2 | 20 | 15 December 2017 | |
| NCT03356795 | Intervention of CAR-T Against Cervical Cancer | Unknown status | Cervical Cancer | Phase 1 Phase 2 | 20 | 15 November 2017 | |
| NCT03323944 | CAR-T-Cell Immunotherapy for Pancreatic Cancer | Active, not recruiting | Pancreatic Cancer | Phase 1 | 8 | 15 September 2017 | |
| NCT03267173 | Evaluation of the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer | Unknown status | Pancreatic Cancer | Early Phase 1 | 10 | 15 June 2017 | |
| NCT03198052 | HER2/Mesothelin/Lewis-Y/PSCA/MUC1/GPC3/AXL/EGFR/B7-H3/Claudin18.2-CAR-T Cell Immunotherapy against Cancers | Recruiting | Lung Cancer | Phase 1 | 30 | 1 July 2017 | |
| NCT03182803 | CTLA-4 and PD-1 Antibodies Expressing Mesothelin-CAR-T Cells for Mesothelin-Positive Advanced Solid Tumor | Unknown status | Advanced Solid Tumor | Phase 1 Phase 2 | 40 | 7 June 2017 | |
| NCT03054298 | CAR-T Cells in Mesothelin-Expressing Cancers | Recruiting | Lung Adenocarcinoma, Ovarian Cancer, Peritoneal Carcinoma, Fallopian Tube Cancer, Pleural Mesothelioma, Peritoneal Mesothelioma | Phase 1 | 27 | 1 March 2017 | |
| NCT03030001 | PD-1 Antibody-Expressing CAR-T Cells for Mesothelin-Positive Advanced Malignancies | Unknown status | Solid Tumor | Phase 1 Phase 2 | 40 | 15 February 2017 | |
| NCT02959151 | A Study of Chimeric Antigen Receptor T Cells Combined with Interventional Therapy in Advanced Liver Malignancy | Unknown status | Hepatocellular carcinoma, Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer | Phase 1 Phase 2 | 20 | 1 July 2016 | |
| NCT02930993 | Anti-Mesothelin CAR-T Cells for Patients with Recurrent or Metastatic Malignant Tumors | Unknown status | Mesothelin-Positive Tumors | Phase 1 | 20 | 1 August 2016 | |
| NCT02792114 | T-Cell Therapy for Advanced Breast Cancer | Active, not recruiting | Metastatic HER2-Negative Breast Cancer | Phase 1 | 186 | 1 June 2016 | |
| NCT02706782 | A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic Carcinoma | Unknown status | Pancreatic Cancer | Phase 1 | 30 | 1 March 2016 | |
| NCT02580747 | Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso | Unknown status | Malignant Mesothelioma, Pancreatic Cancer, Ovarian Tumor, Triple-Negative Breast Cancer, Endometrial Cancer, Other Mesothelin-Positive Tumors | Phase 1 | 20 | 1 October 2015 | |
| NCT02465983 | Pilot Study of Autologous T cells in Patients with Metastatic Pancreatic Cancer | Terminated | Pancreatic Cancer | Phase 1 | 4 | 1 May 2015 | |
| NCT02414269 | Malignant Pleural Disease Treated with Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin | Active, not recruiting | Malignant Pleural Disease, Mesothelioma, Metastases, Lung Cancer, Breast Cancer | Phase 1 Phase 2 | 113 | 1 May 2015 | PMID: 34266984 |
| NCT02388828 | CART-meso Long-Term Follow-up | Completed | Subjects Who Have Received Lentiviral-Based CART-meso Therapy | 10 | 1 March 2015 | ||
| NCT02159716 | CART-meso in Mesothelin-Expressing Cancers | Completed | Metastatic Pancreatic (Ductal) Adenocarcinoma, Epithelial Ovarian Cancer, Malignant Epithelial Pleural Mesothelioma | Phase 1 | 19 | 1 June 2014 | PMID: 31420241 |
| NCT01897415 | Autologous Redirected RNA Meso-CAR-T Cells for Pancreatic Cancer | Completed | Metastatic Pancreatic Ductal Adenocarcinoma (PDA) | Phase 1 | 16 | 1 July 2013 | PMID: 29567081 |
| NCT01583686 | CAR-T-Cell Receptor Immunotherapy Targeting Mesothelin for Patients with Metastatic Cancer | Terminated | Cervical Cancer, Pancreatic Cancer, Ovarian Cancer, Mesothelioma, Lung Cancer | Phase 1 Phase 2 | 15 | 4 May 2012 | |
| NCT01355965 | Autologous Redirected RNA Meso-CAR-T Cells | Completed | Malignant Pleural Mesothelioma | Phase 1 | 18 | 1 May 2011 | PMID: 24579088 |